ClinicalTrials.gg
Active, not recruitingNCT06780449Updated Jan 20, 2026

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

A Phase 3 interventional study of Cagrilintide and Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 36 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Planned enrollment
10th of 36
400 · median 154
Started
2025
with 5 others
Phase 3
15 of 36
4 open now
Primary completion
2028-08
later than 13 of 14 live
Registered
21st of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 10th largest by planned enrollment, is one of 6 that started in 2025, is one of 15 in phase 3, reaches primary completion later than 13 of the 14 other live ones, and was the 21st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Age above or equal to 18 years at the time of signing .
  • (BMI) greater than or equal to (>=) 35.0 kilograms per meter square (kg/m\^2).

Exclusion criteria

Exclusion criteria:

  • (HbA1c) >= 6.5 percent (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    CagriSema

    Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) after a dose escalation period of 16 weeks during the maintenance period for 88 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for one year.

    Drug: Cagrilintide · Drug: Semaglutide

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously once weekly for 104 weeks. Participants randomised to this arm will be included in the extension phase for one year.

    Drug: Placebo cagrilintide · Drug: Placebo semaglutide

Interventions

  • Participants will receive cagrilintide subcutaneously.

  • Participants will receive semaglutide subcutaneously.

  • DrugPlacebo cagrilintide

    Participants will receive placebo matched to cagrilintide subcutaneously.

  • DrugPlacebo semaglutide

    Participants will receive placebo matched to semaglutide subcutaneously.

06

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured in percentage (%).

    Time frame: From baseline (week 0) to week 104

Secondary outcomes

  1. Number of participants who achieve greater than or equal to (>=) 20 percent body weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 104

  2. Number of participants who achieve >= 25 percent body weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 104

  3. Number of participants who achieve >= 30 percent body weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 104

  4. Change in waist circumference

    Measured in centimeter (cm).

    Time frame: From baseline (week 0) to week 104

  5. Change in waist to height ratio

    Measured as ratio.

    Time frame: From baseline (week 0) to week 104

  6. Change in Systolic Blood Pressure (SBP)

    Measured in millimeter of mercury (mmHg).

    Time frame: From baseline (week 0) to week 104

  7. Ratio to Baseline in Lipids: Total Cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 104

  8. Ratio to Baseline in Lipids: High Density Lipoprotein (HDL) Cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 104

  9. Ratio to Baseline in Lipids: Low Density Lipoprotein (LDL) Cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 104

  10. Ratio to Baseline in Lipids: Very Low Density Lipoprotein (VLDL) Cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 104

  11. Ratio to Baseline in Lipids: Triglycerides

    Measured as ratio.

    Time frame: From baseline (week 0) to week 104

  12. Ratio to Baseline in Lipids: Free fatty acids

    Measured as ratio.

    Time frame: From baseline (week 0) to week 104

  13. Ratio to Baseline in Lipids: Non-HDL cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 104

  14. Change in Body Mass Index (BMI)

    Measured in kilograms per meter square (kg/m\^2).

    Time frame: From baseline (week 0) to week 104

  15. Number of participants who achieve BMI less than 30 kg/m^2

    Measured as count of participants.

    Time frame: At week 104

  16. Change in Glycated Haemoglobin (HbA1c) (percentage points)

    Measured in percentage points.

    Time frame: From baseline (week 0) to week 104

  17. Change in HbA1c (millimoles per mole [mmol/mol])

    Measured in mmol/mol.

    Time frame: From baseline (week 0) to week 104

  18. Change in Fasting Plasma Glucose (FPG) (millimoles per liter [mmol/L])

    Measured as mmol/L.

    Time frame: From baseline (week 0) to week 104

  19. Change in FPG (milligrams per deciliter [mg/dL])

    Measured as mg/dL.

    Time frame: From baseline (week 0) to week 104

  20. Number of participants who achieve HbA1c less than (<) 5.7 percent and FPG < 100 mg/dL with prediabetes at baseline

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 104

  21. Number of participants who achieve HbA1c >= 6.5 percent or FPG >= 126 mg/dL with prediabetes at baseline

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 104

  22. Time to HbA1c < 5.7 percent and FPG < 100 mg/dL with prediabetes at baseline

    Measured in days.

    Time frame: From baseline (week 0) to week 104

  23. Time to HbA1c >= 6.5 percent or FPG >= 126 mg/dL with prediabetes at baseline

    Measured in days.

    Time frame: From baseline (week 0) to week 104

  24. Number of participants who develop HbA1c >= 5.7 percent or FPG greater than (>) 100 mg/dL with normoglycemia at baseline

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 104

  25. Number of participants who develop type 2 diabetes (T2D) as per American Diabetes Association (ADA) guideline

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 104

  26. Time to T2D diagnosis as per ADA guideline

    Measured in days.

    Time frame: From baseline (week 0) to week 104

  27. Change in American College of Cardiology/American Heart Association (ACC/AHA) 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk score

    Measured in percentage of risk. American College of Cardiology/American Heart Association (ACC/AHA) risk estimator calculates 10 year risk of atherosclerotic cardiovascular disease (ASCVD) using a formula which includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure medication use, diabetes status, smoking status; minimum score 0, maximum score 100 where higher score indicates higher risk of 10-year risk of atherosclerotic cardiovascular disease (ASCVD).

    Time frame: From baseline (week 0) to week 104

  28. Number of participants who improve in >= 1 pre-existing cardiometabolic obesity related com-plication (ORC) (hypertension, prediabetes, or dyslipidaemia)

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 104

  29. Ratio to baseline in C-reactive protein (CRP)

    Measured as ratio.

    Time frame: From baseline (week 0) to week 104

  30. Change in total fat mass by dual energy X-ray absorption (DXA) absolute to total body mass (kilogram [kg])

    Measured in kg.

    Time frame: From baseline (week 0) to week 104

  31. Change in total fat mass by DXA relative to total body mass (kg)

    Measured in kg.

    Time frame: From baseline (week 0) to week 104

  32. Change in total fat mass by DXA absolute to total body mass (percentage points)

    Measured in percentage points.

    Time frame: From baseline (week 0) to week 104

  33. Change in total fat mass by DXA relative to total body mass (percentage points)

    Measured in percentage points.

    Time frame: From baseline (week 0) to week 104

  34. Change in visceral fat mass by DXA, relative to baseline in visceral fat mass region (percentage)

    Measured in percentage.

    Time frame: From baseline (week 0) to week 104

  35. Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (percentage)

    Measured in percentage.

    Time frame: From baseline (week 0) to week 104

  36. Change in visceral fat mass by DXA, relative to baseline in visceral fat mass region (percentage points)

    Measured in percentage points.

    Time frame: From baseline (week 0) to week 104

  37. Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (percentage points)

    Measured in percentage points.

    Time frame: From baseline (week 0) to week 104

  38. Change in lean body mass by DXA absolute to total body mass (kg)

    Measured in kg.

    Time frame: From baseline (week 0) to week 104

  39. Change in lean body mass by DXA relative to total body mass (kg)

    Measured in kg.

    Time frame: From baseline (week 0) to week 104

  40. Change in lean body mass by DXA absolute to total body mass (percentage points)

    Measured in percentage points.

    Time frame: From baseline (week 0) to week 104

  41. Change in lean body mass by DXA relative to total body mass (percentage points)

    Measured in percentage points.

    Time frame: From baseline (week 0) to week 104

  42. Change in Short Form (SF)-36 Physical functioning score

    Measured as score points. The SF-36v2 acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. The scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical Functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being.

    Time frame: From baseline (week 0) to week 104

  43. Change in Impact of Weight on Quality of Life-Lite for clinical trials (IWQOL-Lite-CT): Physical Function Score

    Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning.

    Time frame: From baseline (week 0) to week 104

  44. Change in IWQOL-Lite-CT: Physical Score

    Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical score ranges from 0 to 100, with higher scores indicating better levels of functioning.

    Time frame: From baseline (week 0) to week 104

  45. Change in IWQOL-Lite-CT: Psychosocial score

    Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Psychosocial score ranges from 0 to 100, with higher scores indicating better levels of functioning.

    Time frame: From baseline (week 0) to week 104

  46. Change in IWQOL-Lite-CT: Total score

    Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Total score ranges from 0 to 100, with higher scores indicating better levels of functioning.

    Time frame: From baseline (week 0) to week 104

  47. Change in Impact of Weight on Daily Activities Questionnaire (IWDAQ) Composite score

    Measured as score points. IWDAQ is an 18-item measure that uses an adaptive design to provide a personalised assessment of daily activity limitations associated with excess weight. At the baseline assessment the study participants choose the 3 activities (items) they would most like to improve the weight loss and rate the degree of limitation in each of these activities. At follow-up assessments, the study participants again rate the degree of current limitation in each of the same 3 activities. The measure yields the IWDAQ composite score with a score range from 3 to 15 with higher scores indicating greater personalised activity limitation.

    Time frame: From baseline (week 0) to week 104

  48. Change in Control of Eating questionnaire (CoEQ): Craving Control score

    Measured as score points. CoEQ is a 19-item multidimensional patient reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving control subscale, the subscale score is reversed so that a higher score represents a greater level of craving control.

    Time frame: From baseline (week 0) to week 104

  49. Change in CoEQ: Positive Mood score

    Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the Positive Mood subscale, item 6 'How anxious have you felt?' is reversed.

    Time frame: From baseline (week 0) to week 104

  50. Change in CoEQ: Craving for Sweets score

    Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving sweets food subscale, higher score represents a greater level of craving.

    Time frame: From baseline (week 0) to week 104

  51. Change in CoEQ: Craving for Savoury score

    Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving savoury food subscale, higher score represents a greater level of craving.

    Time frame: From baseline (week 0) to week 104

  52. Change in CoEQ: Hunger score

    Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the hunger subscale, higher score represents a greater level of craving.

    Time frame: From baseline (week 0) to week 104

  53. Change in CoEQ: Satiety score

    Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the satiety subscale, higher score represents a greater level of craving.

    Time frame: From baseline (week 0) to week 104

  54. CagriSema s.c. 2.4 mg/2.4 mg versus placebo: Number of Treatment Emergent Adverse Events (TEAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to week 104

  55. CagriSema s.c. 2.4 mg/2.4 mg versus placebo: Number of Treatment Emergent Serious Adverse Events (TESAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to week 104

  56. CagriSema s.c. 2.4 mg/2.4 mg versus CagriSema s.c. dose tapering algorithm: Number of TEAEs

    Measured as count of events.

    Time frame: From week 104 to end of study (week 162)

  57. CagriSema s.c. 2.4 mg/2.4 mg versus CagriSema s.c. dose tapering algorithm: Number of TESAEs

    Measured as count of events.

    Time frame: From week 104 to end of study (week 162)

  58. CagriSema 2.4 mg/2.4 mg: Number of TEAEs

    Measured as count of events.

    Time frame: From week 104 to end of study (week 162)

  59. CagriSema 2.4 mg/2.4 mg: Number of TESAEs

    Measured as count of events.

    Time frame: From week 104 to end of study (week 162)

07

Study locations

36 sites
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Aug 2028, 42 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 42 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Feb 10, 2025
Primary completionEst.
Aug 28, 2028
CompletionEst.
Oct 31, 2028
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06780449
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Feb 10, 2025
Primary completion
Aug 28, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Jan 20, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion